Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardlytics, Inc.CDLX · Entity 7603 | Director | November 08, 2022 | November 10, 2022 |
| Evergy, Inc.EVRG · Entity 3282 | Director | April 01, 2020 | April 02, 2020 |
| Plum Acquisition Corp. IIIAPTMU · Entity 83854 | Director | July 27, 2021 | July 27, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardlytics, Inc.
Report date November 08, 2022 · Filed November 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 248,779 |
Reported balance
After 2022-11-08 transaction · row 1
1 source rowRow 1 · 2022-11-08 · Sale · Disposed 6 · Balance 248,779 F1: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on October 6, 2022. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 55,832 |
Reported balance
Holding disclosure · report date 2022-11-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 55,832 F2: The reportable securities are held by the UTMA Custodial account fbo Pierce Grimes. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 53,112 |
Reported balance
Holding disclosure · report date 2022-11-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 53,112 F3: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on October 6, 2022.
F2: The reportable securities are held by the UTMA Custodial account fbo Pierce Grimes.
F3: The reportable securities are held by the 2013 Scott Grimes GRAT UAD.
Evergy, Inc.
Report date April 01, 2020 · Filed April 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 13,666 |
Reported balance
After 2020-04-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-04-01 · Grant · Acquired 455 · Balance 13,666 F1: Director Deferred Share Units represent the right to receive one share of Evergy, Inc. ("Evergy") common stock, plus, if applicable, stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person. F2: Director Deferred Share Units received as partial payment of retainer fees that have been deferred pursuant to elections made by the reporting person. F3: Includes 122 deferred share units acquired through the reinvestment of dividend equivalents. |
| Common StockSEC Table I · non-derivative | Direct | 788 |
Reported balance
Holding disclosure · report date 2020-04-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 788 |
Filing footnotes · ownership attribution and instrument terms
F1: Director Deferred Share Units represent the right to receive one share of Evergy, Inc. ("Evergy") common stock, plus, if applicable, stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person.
F2: Director Deferred Share Units received as partial payment of retainer fees that have been deferred pursuant to elections made by the reporting person.
F3: Includes 122 deferred share units acquired through the reinvestment of dividend equivalents.
Plum Acquisition Corp. III
Report date July 27, 2021 · Filed July 27, 2021
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GREAT PLAINS ENERGY INC
Report date June 04, 2018 · Filed June 05, 2018
Section 16 reporting ended · disclosed 2018-06-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-06-04 transaction · row 1
1 source rowRow 1 · 2018-06-04 · Disposition to issuer · Disposed 1,318 · Balance 0 F1: Disposed of pursuant to that certain Amended and Restated Agreement and Plan of Merger ("Merger Agreement") dated as of July 9, 2017 by and among Great Plains Energy Incorporated ("Great Plains Energy"), Westar Energy, Inc., Evergy, Inc. ("Evergy") (formerly Monarch Energy Holding, Inc.), King Energy, Inc., and for certain limited purposes, GP Star, Inc. in exchange for shares of Evergy common stock at an exchange ratio of 0.5981 for each Great Plains Energy share on the effective date of the merger. On the effective date of the merger, the closing price of Great Plains Energy's common stock was $31.99 per share, and Evergy's common stock had not yet commenced trading on the New York Stock Exchange. |
| Director Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-04 · Disposition to issuer · Disposed 11,970 · Balance 0 F2: Director Deferred Share units are granted under the Long-Term Incentive Plan. Each unit represents the right to receive one share of Great Plains Energy Common Stock, plus stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person. F3: The Great Plains Energy Director Deferred Share units were exchanged for Evergy Director Deferred Share units pursuant to the Merger Agreement at an exchange ratio of 0.5981 for each Great Plains Energy share. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Amended and Restated Agreement and Plan of Merger ("Merger Agreement") dated as of July 9, 2017 by and among Great Plains Energy Incorporated ("Great Plains Energy"), Westar Energy, Inc., Evergy, Inc. ("Evergy") (formerly Monarch Energy Holding, Inc.), King Energy, Inc., and for certain limited purposes, GP Star, Inc. in exchange for shares of Evergy common stock at an exchange ratio of 0.5981 for each Great Plains Energy share on the effective date of the merger. On the effective date of the merger, the closing price of Great Plains Energy's common stock was $31.99 per share, and Evergy's common stock had not yet commenced trading on the New York Stock Exchange.
F2: Director Deferred Share units are granted under the Long-Term Incentive Plan. Each unit represents the right to receive one share of Great Plains Energy Common Stock, plus stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person.
F3: The Great Plains Energy Director Deferred Share units were exchanged for Evergy Director Deferred Share units pursuant to the Merger Agreement at an exchange ratio of 0.5981 for each Great Plains Energy share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2021 Filed Feb 24, 2021 21:14 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 300 | $134.33 | $40,299.00 |
DisclosureSEC source: 0001666071-21-000013 · wf-form4_161420118568159.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,608 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $134.16 to $134.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 22:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 100 | $160.60 | $16,060.00 |
DisclosureSEC source: 0001666071-21-000012 · wf-form4_161360090969327.xml · nonDerivative · entry 5 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 93,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 22:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 100 | $159.21 | $15,921.00 |
DisclosureSEC source: 0001666071-21-000012 · wf-form4_161360090969327.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 93,212 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 22:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 692 | $158.82 | $109,903.44 |
DisclosureSEC source: 0001666071-21-000012 · wf-form4_161360090969327.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 93,312 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $158.21 to $159.17, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 22:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 310 | $156.72 | $48,583.20 |
DisclosureSEC source: 0001666071-21-000012 · wf-form4_161360090969327.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 94,004 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $156.64 to $156.76, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 22:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 798 | $155.32 | $123,945.36 |
DisclosureSEC source: 0001666071-21-000012 · wf-form4_161360090969327.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 94,314 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $155.02 to $155.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (5) to this Form 4. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 21:06 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,500 | $133.25 | $199,875.00 |
DisclosureSEC source: 0001666071-21-000008 · wf-form4_161238638429587.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 95,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $132.97 to $133.42, inclusive. F2 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 21:06 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $131.34 | $26,268.00 |
DisclosureSEC source: 0001666071-21-000008 · wf-form4_161238638429587.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 96,612 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $131.04 to $131.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. F2 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 21:06 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 100 | $129.85 | $12,985.00 |
DisclosureSEC source: 0001666071-21-000008 · wf-form4_161238638429587.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 96,812 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 21:06 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $126.88 | $25,376.00 |
DisclosureSEC source: 0001666071-21-000008 · wf-form4_161238638429587.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 96,912 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 22:31 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1 | $126.67 | $126.67 |
DisclosureSEC source: 0001666071-21-000007 · wf-form4_161170027536519.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,908 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 22:31 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 999 | $125.31 | $125,184.69 |
DisclosureSEC source: 0001666071-21-000007 · wf-form4_161170027536519.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,909 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $124.91 to $125.73, inclusive. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 22:31 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 600 | $124.15 | $74,490.00 |
DisclosureSEC source: 0001666071-21-000007 · wf-form4_161170027536519.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,908 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $123.90 to $124.58, inclusive. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 22:31 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 400 | $123.03 | $49,212.00 |
DisclosureSEC source: 0001666071-21-000007 · wf-form4_161170027536519.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,508 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $122.60 to $123.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:37 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $118.07 | $23,614.00 |
DisclosureSEC source: 0001666071-21-000006 · wf-form4_161117862061496.xml · nonDerivative · entry 5 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 97,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F7 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $117.80 to $118.33, inclusive. F3 · ownership.nature: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:37 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 400 | $116.34 | $46,536.00 |
DisclosureSEC source: 0001666071-21-000006 · wf-form4_161117862061496.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 97,312 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $116.07 to $116.84, inclusive. F3 · ownership.nature: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:37 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 400 | $115.05 | $46,020.00 |
DisclosureSEC source: 0001666071-21-000006 · wf-form4_161117862061496.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 97,712 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $114.81 to $115.44, inclusive. F3 · ownership.nature: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:37 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 500 | $114.14 | $57,070.00 |
DisclosureSEC source: 0001666071-21-000006 · wf-form4_161117862061496.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 98,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $113.65 to $114.37, inclusive. F3 · ownership.nature: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:37 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 500 | $112.68 | $56,340.00 |
DisclosureSEC source: 0001666071-21-000006 · wf-form4_161117862061496.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 98,612 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $112.24 to $113.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6) and (7) to this Form 4. F3 · ownership.nature: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $140.15 | $28,030.00 |
DisclosureSEC source: 0001666071-21-000001 · wf-form4_160988569438726.xml · nonDerivative · entry 5 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 99,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F3 · ownership.nature: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 101 | $139.65 | $14,104.65 |
DisclosureSEC source: 0001666071-21-000001 · wf-form4_160988569438726.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 99,312 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $139.08 to $139.66, inclusive. F3 · ownership.nature: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 498 | $138.16 | $68,803.68 |
DisclosureSEC source: 0001666071-21-000001 · wf-form4_160988569438726.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 99,413 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $137.75 to $138.65, inclusive. F3 · ownership.nature: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 363 | $136.78 | $49,651.14 |
DisclosureSEC source: 0001666071-21-000001 · wf-form4_160988569438726.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 99,911 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $136.33 to $137.19, inclusive. F3 · ownership.nature: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 838 | $135.82 | $113,817.16 |
DisclosureSEC source: 0001666071-21-000001 · wf-form4_160988569438726.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 100,274 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $135.29 to $136.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5) and (6) to this Form 4. F3 · ownership.nature: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. Read SEC document |
| December 31, 2020 Filed Dec 20, 2021 22:41 UTC | Cardlytics, Inc. CDLX · Entity 7603 | OtherCommon Stock | 55,832 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-21-000247 · wf-form4_164004006562778.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 55,832 F1 · ownership.nature: The reportable securities are held by the UTMA Custodial account fbo Pierce Grimes. Read SEC document |
| December 23, 2020 Filed Dec 23, 2020 22:20 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 564 | $147.36 | $83,111.04 |
DisclosureSEC source: 0001666071-20-000310 · wf-form4_160876199196103.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,908 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $146.83 to $147.64, inclusive. Read SEC document |
| December 23, 2020 Filed Dec 23, 2020 22:20 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 300 | $145.74 | $43,722.00 |
DisclosureSEC source: 0001666071-20-000310 · wf-form4_160876199196103.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,472 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $145.54 to $145.90, inclusive. Read SEC document |
| December 23, 2020 Filed Dec 23, 2020 22:20 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 936 | $144.76 | $135,495.36 |
DisclosureSEC source: 0001666071-20-000310 · wf-form4_160876199196103.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,772 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $144.27 to $145.20, inclusive. Read SEC document |
| December 23, 2020 Filed Dec 23, 2020 22:20 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $143.55 | $28,710.00 |
DisclosureSEC source: 0001666071-20-000310 · wf-form4_160876199196103.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,708 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $143.19 to $143.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:10 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 600 | $136.14 | $81,684.00 |
DisclosureSEC source: 0001666071-20-000308 · wf-form4_160832584113189.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 101,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $135.92 to $136.45, inclusive. F3 · ownership.nature: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:10 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,200 | $135.13 | $162,156.00 |
DisclosureSEC source: 0001666071-20-000308 · wf-form4_160832584113189.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 101,712 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $134.70 to $135.48, inclusive. F3 · ownership.nature: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:10 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $133.90 | $26,780.00 |
DisclosureSEC source: 0001666071-20-000308 · wf-form4_160832584113189.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 102,912 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $133.57 to $134.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (5) to this Form 4. F3 · ownership.nature: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. Read SEC document |
| December 14, 2020 Filed Dec 30, 2020 21:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 300 | $138.94 | $41,682.00 |
DisclosureSEC source: 0001666071-20-000311 · wf-form4_160936293104754.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,908 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $138.81 to $139.06, inclusive. Read SEC document |
| December 14, 2020 Filed Dec 30, 2020 21:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 831 | $137.82 | $114,528.42 |
DisclosureSEC source: 0001666071-20-000311 · wf-form4_160936293104754.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,208 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $137.39 to $138.19, inclusive. Read SEC document |
| December 14, 2020 Filed Dec 30, 2020 21:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 469 | $136.83 | $64,173.27 |
DisclosureSEC source: 0001666071-20-000311 · wf-form4_160936293104754.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,039 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $136.37 to $137.29, inclusive. Read SEC document |
| December 14, 2020 Filed Dec 30, 2020 21:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 400 | $135.51 | $54,204.00 |
DisclosureSEC source: 0001666071-20-000311 · wf-form4_160936293104754.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,508 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $135.32 to $135.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 21:04 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 300 | $120.61 | $36,183.00 |
DisclosureSEC source: 0001666071-20-000302 · wf-form4_160702948341521.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 103,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $120.29 to $120.77, inclusive. F3 · ownership.nature: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 21:04 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 300 | $119.32 | $35,796.00 |
DisclosureSEC source: 0001666071-20-000302 · wf-form4_160702948341521.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 103,412 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $118.98 to $119.86, inclusive. F3 · ownership.nature: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 21:04 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 300 | $118.02 | $35,406.00 |
DisclosureSEC source: 0001666071-20-000302 · wf-form4_160702948341521.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 103,712 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $117.57 to $118.26, inclusive. F3 · ownership.nature: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 21:04 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,100 | $115.31 | $126,841.00 |
DisclosureSEC source: 0001666071-20-000302 · wf-form4_160702948341521.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 104,012 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $114.82 to $115.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5) and (6) to this Form 4. F3 · ownership.nature: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. Read SEC document |
| November 27, 2020 Filed Nov 30, 2020 22:09 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $120.69 | $24,138.00 |
DisclosureSEC source: 0001666071-20-000295 · wf-form4_160677416757786.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,750 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for PSUs that vested on November 25, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $120.68 to $120.69, inclusive. Read SEC document |
| November 27, 2020 Filed Nov 30, 2020 22:09 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 6,701 | $119.87 | $803,248.87 |
DisclosureSEC source: 0001666071-20-000295 · wf-form4_160677416757786.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,950 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for PSUs that vested on November 25, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $119.47 to $120.45, inclusive. Read SEC document |
| November 27, 2020 Filed Nov 30, 2020 22:09 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 2,232 | $119.19 | $266,032.08 |
DisclosureSEC source: 0001666071-20-000295 · wf-form4_160677416757786.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,651 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for PSUs that vested on November 25, 2020. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $118.45 to $119.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4) and (5) to this Form 4. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 22:09 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionPerformance Stock Unit · Derivative | 19,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-20-000295 · wf-form4_160677416757786.xml · derivative · entry 6 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: On November 25, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a minimum cumulative adjusted EBITDA target over a trailing 12-month period of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the adjusted EBITDA target ("EBITDA tranche"). Fifty percent (50%) of the shares subject to the EBITDA tranche of the awarded PSU vested upon the Certification and were delivered on November 25, 2019. Twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU vested on May 25, 2020, 6 months after the Certification. The final twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU vested on November 25, 2020, 12 months after the Certification. F7 · derivative.expiration_date: On November 25, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a minimum cumulative adjusted EBITDA target over a trailing 12-month period of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the adjusted EBITDA target ("EBITDA tranche"). Fifty percent (50%) of the shares subject to the EBITDA tranche of the awarded PSU vested upon the Certification and were delivered on November 25, 2019. Twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU vested on May 25, 2020, 6 months after the Certification. The final twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU vested on November 25, 2020, 12 months after the Certification. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 22:09 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 19,687 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001666071-20-000295 · wf-form4_160677416757786.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 22:50 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,100 | $114.55 | $126,005.00 |
DisclosureSEC source: 0001666071-20-000289 · wf-form4_160565344388600.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 105,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $114.26 to $115.12, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 22:50 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 900 | $113.83 | $102,447.00 |
DisclosureSEC source: 0001666071-20-000289 · wf-form4_160565344388600.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 106,212 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $113.17 to $114.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| November 09, 2020 Filed Nov 11, 2020 01:45 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionRestricted Stock Units · Derivative | 350 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-20-000284 · wf-form4_160505910058463.xml · derivative · entry 5 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. F5 · derivative.exercise_date: The RSUs are immediately vested. F5 · derivative.expiration_date: The RSUs are immediately vested. Read SEC document |
| November 09, 2020 Filed Nov 11, 2020 01:45 UTC | Cardlytics, Inc. CDLX · Entity 7603 | GrantRestricted Stock Units · Derivative | 350 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-20-000284 · wf-form4_160505910058463.xml · derivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350 Underlying: Common Stock · 350 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. F5 · derivative.exercise_date: The RSUs are immediately vested. F5 · derivative.expiration_date: The RSUs are immediately vested. Read SEC document |
| November 09, 2020 Filed Nov 11, 2020 01:45 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 144 | $100.40 | $14,457.60 |
DisclosureSEC source: 0001666071-20-000284 · wf-form4_160505910058463.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,996 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs granted on November 9, 2020. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $100.33 to $100.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.